Please assess the completion status of the following clinical trial:

Trial Title: Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* willing and able to provide written informed consent for the study.~* ≥ 18 years of age on day of signing informed consent.~* confirmed diagnosis of NSCLC.~* Histological tumor biopsy for PD-L1 IHC assessment (DAKO assay) available.~* Ipsilateral hilar or mediastinal lymph node with a short axis diameter ≥1 cm.~* Eligible and planned to receive nivolumab according to EMA label and national guidelines.~* Measurable disease according to RECIST v1.1.~* WHO performance status of 0-2.~Exclusion Criteria:~* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to baseline PET-scan.~* Has an active infection or had an active infection within 2 weeks prior to baseline PET-scan.~* Has a known history of hypersensitivity to contrast material.~* Isolated distant relapse after curative intent treatment for stage I-III NSCLC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: OTHER): Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation

Based on this trial design, predict the completion outcome and termination type (if applicable).